Striational antibodies in a paraneoplastic context
Article first published online: 5 MAR 2013
Copyright © 2013 Wiley Periodicals, Inc.
Muscle & Nerve
Volume 47, Issue 4, pages 585–587, April 2013
How to Cite
McKeon, A., Lennon, V. A., LaChance, D. H., Klein, C. J. and Pittock, S. J. (2013), Striational antibodies in a paraneoplastic context. Muscle Nerve, 47: 585–587. doi: 10.1002/mus.23774
- Issue published online: 25 MAR 2013
- Article first published online: 5 MAR 2013
- Accepted manuscript online: 30 JAN 2013 10:50PM EST
- Manuscript Accepted: 31 DEC 2012
The clinical significance of striational antibodies (StrAbs) detected in the course of paraneoplastic antibody testing is unknown.
We compared all 203 striational antibody (StrAb)-seropositive patients identified (2004–2005) during evaluation for paraneoplastic antibodies with age- and sex-matched seronegative controls.
Thymoma and myasthenia gravis (MG) were significantly more common among cases (P<0.0001). Cancers more rarely detected after StrAb detection were adenocarcinoma in 5 patients and sarcoma in 3 patients. All patients who had a cancer identified after StrAb testing had a titer of ≥1:7680 or a coexisting muscle AChR-binding antibody. Autoimmune disorders more commonly observed among cases (with any StrAb value) included: hypothyroidism; rheumatoid arthritis; and pernicious anemia (all P<0.05).
StrAbs may serve as a diagnostic clue for an autoimmune diagnosis. There is a low likelihood of oncological significance in patients with StrAb titers <1:7680 without coexisting paraneoplastic Abs. Muscle Nerve, 2013